The SeroTag® Platform
SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.
This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag® is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.
The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies. SeroTag® analyzes autoantibodies—some of the most stable analytes—and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.
The SeroTag® platform acts as the primary discovery engine that feeds into the creation of Protagen’s NavigAID disease-specific stratification panels—precision medicine tools which are enabling patient and disease stratification and support therapeutic development.
Read on to find out more about how SeroTag® is applied to autoimmune diseases and immuno-oncology.
SeroTag® for autoimmune disease
The pathology of autoimmune diseases is intricate, and is characterized by a complex, maladaptive response of the immune system. This underlying process provides us with a window of opportunity, as autoantibodies are often produced early during the development of autoimmune diseases (sometimes even years before diagnosis), which can often provide insights into how a disease will manifest and progress. This makes them the biomarker of choice for autoimmune diseases.
To date, autoantibodies have not been analyzed systematically in this field, and their potential to define the status of a patient’s immune-competence and responsiveness to treatment remains largely untapped.
Protagen is applying its SeroTag® platform to identify novel biomarkers, enabling patient subgrouping within autoimmune diseases—thereby supporting the successful development of herapies.
As a result of its SeroTag® work, Protagen has already developed the NavigAID range of stratification arrays for a number of indications, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s Disease (SjS) and others.
In addition, SeroTag® has also been used for the development of a number of in vitro diagnostic products for multiple autoimmune indications, such as the Multilisa BICD2 panel for SSc. This forms part of Protagen’s unique cascade, from initial discovery through validation and commercialization.
To find out more about how SeroTag® and our NavigAID tools are helping to advance the field of autoimmune disease, click here.
SeroTag® for immuno-oncology
As well as playing a key role in the pathology of autoimmune diseases, the activity of autoantibodies in patients set to receive (or currently receiving) cancer immunotherapy offers a unique opportunity to support the development of safer, more effective immuno-oncology treatments.
Although the significance of autoantibodies in immuno-oncology is now being recognized, a systematic analysis has yet to be performed. Such autoantibody discovery and the immuno-profiling of patients holds great promise to address challenges such as cancer immunotherapy response prediction, as well as the prediction and monitoring of irAEs.
SeroTag® is currently being used to do exactly this. In line with our work in autoimmune diseases, SeroTag® enables the discovery and development of minimally-invasive liquid biopsy biomarkers, which is helping to expand Protagen’s NavigAID offering to support the development of immunotherapeutic anticancer drugs.
Through our partnerships and strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA and Gustave Roussy (GR) in France, we have already successfully applied SeroTag® to a number of indications and immunotherapies and have been able to demonstrate that the platform is enabling the immuno-profiling of IO patients.
To find out more about how SeroTag® is helping to advance the field of immuno-oncology, contact us.
Protagen has developed a pipeline of NavigAID stratification arrays, based on autoantibody signatures, for a number of autoimmune diseases to help overcome issues such as patient heterogeneity.
Protagen is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy.
Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs, owing to the role played by autoantibodies in cancer as well as autoimmune disease.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.